Literature DB >> 28847691

Reply by the Authors.

Daniel T Oberlin1, William J Catalona, Joshua J Meeks2.   

Abstract

Entities:  

Year:  2017        PMID： 28847691      PMCID： PMC5994913          DOI： 10.1016/j.urology.2017.08.023

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  5 in total

1.  The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.

Authors:  Michael Kongnyuy; Abhinav Sidana; Arvin K George; Akhil Muthigi; Amogh Iyer; Michele Fascelli; Meet Kadakia; Thomas P Frye; Richard Ho; Francesca Mertan; M Minhaj Siddiqui; Daniel Su; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Urol Oncol       Date:  2016-02-20       Impact factor: 3.498

2.  Magnetic resonance imaging targeted biopsy in men with previously negative prostate biopsy results.

Authors:  Seung Hwan Lee; Mun Su Chung; Joo Hee Kim; Young Taik Oh; Koon Ho Rha; Byung Ha Chung
Journal:  J Endourol       Date:  2012-05-08       Impact factor: 2.942

3.  Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy.

Authors:  Byung Kwan Park; Hyun Moo Lee; Chan Kyo Kim; Han Yong Choi; Jong Wook Park
Journal:  Invest Radiol       Date:  2008-11       Impact factor: 6.016

4.  Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?

Authors:  Pietro Pepe; Antonio Garufi; Giandomenico Priolo; Michele Pennisi
Journal:  Clin Genitourin Cancer       Date:  2014-06-21       Impact factor: 2.872

5.  A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.

Authors:  James S Wysock; Andrew B Rosenkrantz; William C Huang; Michael D Stifelman; Herbert Lepor; Fang-Ming Deng; Jonathan Melamed; Samir S Taneja
Journal:  Eur Urol       Date:  2013-11-08       Impact factor: 20.096
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.